Document:

EX-10.10

 Exhibit 10.10 

FORWARD PURCHASE AGREEMENT 

This Forward Purchase Agreement (this “Agreement”) is entered into as of September 23, 2020, among TPG Pace Tech
Opportunities Corp., a Cayman Islands exempted limited company (the “Company”), and other third parties (each, a “Purchaser”, and collectively, the “Purchasers”). The amount of Units (as defined
below) subject to forward purchase by each Purchaser will be set forth, from time to time, in an appendix hereto (as may be amended from time to time without further input from the Company). 

RECITALS 
 WHEREAS, the
Company was formed for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”); 

WHEREAS, the Company has filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 (the “Registration Statement”) for its initial public offering (“IPO”) of 45,000,000 units (or 51,750,000 units if the IPO over-allotment option is exercised in full), which
amounts may be adjusted in connection with the Company’s marketing efforts relating to the IPO (the units so issued in the IPO, including any units issued in connection with an over-allotment exercise, are referred to herein as the
“Units”), at a price of $10.00 per Unit, each Unit comprised of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Shares,” and the Class A Shares
included in the Units, the “Public Shares”), and one-fifth of one redeemable warrant (a “Redeemable Warrant”), where each whole Redeemable Warrant is exercisable to purchase
one Class A Share at an exercise price of $11.50 per share; 
 WHEREAS, following the closing of the IPO (the
“IPO Closing”), the Company will seek to identify and consummate a Business Combination; 
 WHEREAS, TPG Holdings III, L.P.
(“TPG Holdings III”), a Delaware limited partnership, will enter into a forward purchase agreement, pursuant to which, immediately prior to consummation of the Company’s Business Combination (the “Business Combination
Closing”)), the Company shall issue and sell to TPG Holdings III, and TPG Holdings III shall purchase in the aggregate from the Company, on a private placement basis, no less than $50,000,000 of forward purchase securities,
consisting of 5,000,000 Class A Shares at a price of $10.00 per Class A Share, plus an aggregate of 1,000,000 forward purchase warrants to purchase one Class A Share at $11.50 per share, at an aggregate purchase price of $50,000,000;
and 
 WHEREAS, pursuant to this Agreement, immediately prior to the Business Combination Closing), the Purchasers shall purchase in the
aggregate from the Company, on a private placement basis, up to $100,000,000 of forward purchase securities, consisting of up to 10,000,000 Class A Shares at a price of $10.00 per Class A Share (the “Forward Purchase
Shares”), plus an aggregate of up to 2,000,000 forward purchase warrants to purchase one Class A Share at $11.50 per share (such warrants, together with the Forward Purchase Shares, the “Forward Purchase Securities”),
at an aggregate purchase price of up to $100,000,000 (the “Forward Purchase Price”), in accordance with Section 1 herein and otherwise in accordance with the terms and conditions set forth herein. 

 NOW, THEREFORE, in consideration of the premises, representations, warranties and the mutual
covenants contained in this Agreement, and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

AGREEMENT 
  

	 	1.	 Sale and Purchase. 

(a)    Forward Purchase Securities. 

(i)    Forward Purchase. As provided in this Agreement, immediately prior to the Business
Combination Closing, the Purchasers shall purchase up to $100,000,000 of Forward Purchase Securities, consisting of up to 10,000,000 Forward Purchase Shares at a price of $10.00 per Forward Purchase Share, together with an aggregate of up to
2,000,000 Forward Purchase Warrants, and each Purchaser shall severally and not jointly purchase such number of Forward Purchase Shares and Forward Purchase Warrants as set forth on such Purchaser’s signature page (the “Forward
Purchase”). The Forward Purchase shall be effectuated, if at all, in one or more private placements of Forward Purchase Securities. The Forward Purchase is subject to the approval of the Company’s board of directors (“Board of
Directors”). The Company and the Purchasers may determine, by mutual agreement, to increase the number of Forward Purchase Securities at any time prior to the Company’s Business Combination. 

(ii)    The Company shall require the Purchasers to purchase the Forward Purchase Securities by delivering
notice (a “Notice”) to each Purchaser, at least ten (10) Business Days before the funding of the Forward Purchase Price, specifying the anticipated date of the Business Combination Closing. At least two (2) Business Days
before the anticipated date of the Business Combination Closing specified in each Notice, each Purchaser shall fund the Forward Purchase Price in an amount set forth in each respective Notice in full in free and clear funds (to an account notified
by the Company to the Purchaser). If the Business Combination Closing does not occur within ten (10) days after the Purchasers fund the Forward Purchase Price in full, each respective amount of the Forward Purchase Price shall automatically
return to each respective Purchaser, provided that the return of the Forward Purchase Price shall not terminate the Agreement or otherwise relieve any party of any of its obligations hereunder. For the purposes of this Agreement,
“Business Day” means any day, other than a Saturday or a Sunday, that is neither a legal holiday nor a day on which banking institutions are generally authorized or required by law or regulation to close in the City of New York, New
York. Each Purchaser’s obligation to consummate the Forward Purchase set forth in this Section 1(a)(ii) shall not be transferable or assignable by each Purchaser. 

(iii)    The closing of the sale of the Forward Purchase Securities by each Purchaser (the “Forward
Closing”) shall be held on the same date and immediately prior to the Business Combination Closing. At the Forward Closing, the Company shall issue to each Purchaser the Forward Purchase Securities, equal to the amount of the Forward
Purchase set forth in each Notice. 

  
 2 

 (iv)    At the Forward Closing, if agreed by the
Purchaser and TPG Pace Tech Opportunities Sponsor, Series LLC, in writing in connection with the Purchaser entering into this Agreement, the Company shall also issue to each such Purchaser, on a private placement basis, upon payment of the Forward
Purchase Price, an additional number of Class A Shares (the “Additional Shares” and, together with the Forward Purchase Securities, the “Securities”). 

(v)    At the Forward Closing, upon payment of the Forward Purchase Price, the Company shall issue the
Securities to the Purchasers in book-entry form, free and clear of any liens or other restrictions whatsoever (other than those arising under state or federal securities laws), registered in the name of each Purchaser, or to a custodian designated
by each Purchaser, as applicable, pursuant to written instructions delivered by each Purchaser. 

(b)    Legends. Each book entry for the Securities shall contain a notation, and each certificate (if any)
evidencing the Securities shall be stamped or otherwise imprinted with a legend, in substantially the following form: 

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE TRANSFERRED IN VIOLATION OF SUCH ACT AND LAWS. THE SALE, PLEDGE, HYPOTHECATION, OR TRANSFER OF THE SECURITIES REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN
FORWARD PURCHASE AGREEMENT BY AND AMONG THE HOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.” 

(c)    Certificates. The Company shall cooperate with a Purchaser, at its request, to facilitate the timely
preparation and delivery of physical certificates representing the Securities and enable such certificates to be in such denominations or amounts, as the case may be, as the Purchasers may reasonably request and registered in such names as the
Purchasers may request. Any such physical certificates shall be stamped or otherwise imprinted with a legend substantially in the form set forth in Section 1(b). 

(d)    Legend Removal. If the Securities are eligible to be sold without restriction under, and without the Company
being in compliance with the current public information requirements of, Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), then at the Purchasers’ request, the Company will cause the Company’s
transfer agent to remove the legend set forth in Section 1(b) and Section 1(c). In connection therewith, if required by the Company’s transfer agent, the Company will promptly cause an opinion
of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations, certificates and directions required by the transfer agent that authorize and direct the transfer agent to issue such Securities without
any such legend. 

  
 3 

 2.        Representations and Warranties
of the Purchasers. Each Purchaser represents and warrants to the Company as follows, as of the date hereof: 

(a)    Organization and Power. The Purchaser is duly organized, validly existing, and in good standing under the
laws of the jurisdiction of its formation and has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted. 

(b)    Authorization. The Purchaser has full power and authority to enter into this Agreement. This Agreement, when
executed and delivered by the Purchaser, will constitute the valid and legally binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Registration Rights (as defined below) may be limited by applicable federal or state securities laws. 

(c)    Governmental Consents and Filings. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Purchaser in connection with the consummation of the transactions contemplated by this Agreement. 

(d)    Compliance with Other Instruments. The execution, delivery and performance by the Purchaser of this
Agreement and the consummation by the Purchaser of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of its organizational documents, (ii) of any instrument, judgment, order,
writ or decree to which it is a party or by which it is bound, (iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement, contract or purchase order to which it is a party
or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable to the Purchaser, in each case (other than clause (i)), which would have a material adverse effect on the Purchaser or its ability to
consummate the transactions contemplated by this Agreement. 
 (e)    Purchase Entirely for Own Account. This
Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Securities to be acquired by the Purchaser
will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of any state or federal securities laws, and that the Purchaser has
no present intention of selling, granting any participation in, or otherwise distributing the same in violation of law (other than as set forth herein). By executing this Agreement, the Purchaser further represents that the Purchaser does not
presently have any contract, undertaking, agreement or arrangement with any Person (other than another Purchaser) to sell, transfer or grant participations to such Person, with respect to any of the Securities. For purposes of this Agreement,
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or any government or any department or agency thereof. 

  
 4 

 (f)    Disclosure of Information. The Purchaser has had an
opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Securities, as well as the terms of the Company’s proposed IPO, with the Company’s management. 

(g)    Restricted Securities. The Purchaser understands that the offer and sale of the Securities to the Purchaser
has not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the
accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Securities are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these
laws, the Purchaser must hold the Securities indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that
the Company has no obligation to register or qualify the Securities for resale, except as provided herein (the “Registration Rights”). The Purchaser further acknowledges that if an exemption from registration or qualification is
available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Purchaser’s
control, and which the Company is under no obligation and may not be able to satisfy. The Purchaser understands that the offering of the Securities is not and is not intended to be part of the IPO, and that the Purchaser will not be able to rely on
the protection of Section 11 of the Securities Act with respect to such Securities. 
 (h)    No Public
Market. The Purchaser understands that no public market now exists for the Securities, and that the Company has made no assurances that a public market will ever exist for the Securities. 

(i)    High Degree of Risk. The Purchaser understands that its agreement to purchase the Securities involves a high
degree of risk which could cause the Purchaser to lose all or part of its investment. 
 (j)    Accredited
Investor. The Purchaser is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

(k)    No General Solicitation. Neither the Purchaser, nor, to its knowledge, any of its officers, directors,
employees, agents, shareholders or partners has either directly or indirectly, including, through a broker or finder (i) to its knowledge, engaged in any general solicitation, or (ii) published any advertisement in connection with the
offer and sale of the Securities. 
 (l)    Residence. The Purchaser’s principal place of business is the
office or offices located at the address of the Purchaser set forth on the signature page hereof. 
 (m)    Non-Public Information. The Purchaser acknowledges its obligations under applicable securities laws with respect to the treatment of material non-public information
relating to the Company. 

  
 5 

 (n)    Adequacy of Financing. The Purchaser has available to it
sufficient funds to satisfy its obligations under this Agreement. 
 (o)    Affiliation of Certain FINRA Members.
The Purchaser is neither a person associated nor affiliated with Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., Northland Securities, Inc. and Siebert Williams Shank & Co., LLC or, to its actual knowledge,
any other member of the Financial Industry Regulatory Authority (“FINRA”) that is participating in the IPO. 

(p)    No Other Representations and Warranties; Non-Reliance. Except for
the specific representations and warranties contained in this Section 2 and in any certificate or agreement delivered pursuant hereto, none of the Purchaser nor any person acting on behalf of the Purchaser nor any of the
Purchaser’s affiliates (the “Purchaser Parties”) has made, makes or shall be deemed to make any other express or implied representation or warranty with respect to the Purchaser and this offering, and the Purchaser Parties
disclaim any such representation or warranty. Except for the specific representations and warranties expressly made by the Company in Section 3 of this Agreement and in any certificate or agreement delivered pursuant
hereto, the Purchaser Parties specifically disclaim that they are relying upon any other representations or warranties that may have been made by the Company, any person on behalf of the Company or any of the Company’s affiliates (collectively,
the “Company Parties”). 
 3.        Representations and Warranties of
the Company. The Company represents and warrants to the Purchasers as follows: 
 (a)    Organization and
Corporate Power. The Company is an exempted company duly incorporated and validly existing and in good standing as an exempted company under the laws of the Cayman Islands and has all requisite corporate power and authority to carry on its
business as presently conducted and as proposed to be conducted. The Company has no subsidiaries. 

(b)    Capitalization. On the date hereof, the authorized share capital of the Company consists of: 

(i)    200,000,000 Class A Shares, par value $0.0001 per share, none of which are issued and
outstanding. 
 (ii)    20,000,000 Class F ordinary shares of the Company, par value $0.0001 per
share (the “Class F Shares”), 20,000,000 of which are issued and outstanding as of the date hereof. All of the issued and outstanding Class F Shares have been duly authorized, are fully paid and nonassessable
and were issued in compliance with all applicable federal and state securities laws. 

(iii)    1,000,000 preferred shares, par value $0.0001 per share, none of which are issued and outstanding.

 (c)    Authorization. All corporate action required to be taken by the Company’s Board of Directors and
shareholders in order to authorize the Company to enter into this Agreement and to issue the Securities, and the securities issuable upon conversion of exercise of 

  
 6 

 
the Securities, has been taken or will be taken prior to the Forward Closing, including all corporate action required to authorize the issuance of the related Redeemable Warrants. All action on
the part of the shareholders, directors and officers of the Company necessary for the execution and delivery of this Agreement, the performance of all obligations of the Company under this Agreement to be performed as of the Forward Closing, and the
issuance and delivery of the Securities and the securities issuable upon conversion or exercise of the Securities has been taken or will be taken prior to the Forward Closing. This Agreement, when executed and delivered by the Company, shall
constitute the valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or
other laws of general application relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or
(iii) to the extent the indemnification provisions contained in the Registration Rights may be limited by applicable federal or state securities laws. 

(d)    Valid Issuance of Securities. 

(i)    The Securities, when issued, sold and delivered in accordance with the terms and for the
consideration set forth in this Agreement and registered in the register of members of the Company, and the securities issuable upon conversion or exercise of the Securities and this Agreement, and registered in the register of members of the
Company, will be validly issued, fully paid and nonassessable, as applicable, and free of all preemptive or similar rights, liens, encumbrances and charges with respect to the issue thereof and restrictions on transfer other than restrictions on
transfer specified under this Agreement, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Purchaser. Assuming the accuracy of the representations of the Purchasers in this Agreement and subject to
the filings described in Section 3(e) below, the Securities and the securities issuable upon conversion or exercise of the Securities will be issued in compliance with all applicable federal and state securities laws. 

(ii)    No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the
Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge, any Company Covered Person (as defined below), except for a Disqualification Event as to which Rule 506(d)(2)(ii—iv)
or (d)(3), is applicable. “Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1). 

(e)    Governmental Consents and Filings. Assuming the accuracy of the representations and warranties made by the
Purchasers in this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in
connection with the consummation of the transactions contemplated by this Agreement, except for filings pursuant to Regulation D of the Securities Act, applicable state securities laws, if any, and pursuant to the Registration Rights. 

  
 7 

 (f)    Compliance with Other Instruments. The execution, delivery
and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of the Charter or other governing documents of the Company, (ii) of
any instrument, judgment, order, writ or decree to which the Company is a party or by which it is bound, (iii) under any note, indenture or mortgage to which the Company is a party or by which it is bound, (iv) under any lease, agreement,
contract or purchase order to which the Company is a party or by which it is bound or (v) of any provision of federal or state statute, rule or regulation applicable to the Company, in each case (other than clause (i)) which would have a
material adverse effect on the Company or its ability to consummate the transactions contemplated by this Agreement. 

(g)    Operations. As of the date hereof, the Company has not conducted, and prior to the IPO Closing the Company
will not conduct, any operations other than organizational activities and activities in connection with offerings of its securities. 

(h)    No General Solicitation. Neither the Company, nor any of its officers, directors, employees, agents or
shareholders has either directly or indirectly, including, through a broker or finder (i) engaged in any general solicitation, or (ii) published any advertisement in connection with the offer and sale of the Securities. 

(i)    No Other Representations and Warranties; Non-Reliance. Except for
the specific representations and warranties contained in this Section 3 and in any certificate or agreement delivered pursuant hereto, none of the Company Parties has made, makes or shall be deemed to make any other express
or implied representation or warranty with respect to the Company, this offering, the proposed IPO or a potential Business Combination, and the Company Parties disclaim any such representation or warranty. Except for the specific representations and
warranties expressly made by the Purchasers in Section 2 of this Agreement and in any certificate or agreement delivered pursuant hereto, the Company Parties specifically disclaim that they are relying upon any other
representations or warranties that may have been made by the Purchaser Parties. 

4.        Registration Rights 

(a)    Registration. The Company agrees that the Purchasers shall have the registration rights set forth on
Exhibit A. 
 (b)    Indemnification. 

(i)    The Company shall, notwithstanding any termination of this Agreement, indemnify, defend and hold
harmless each Purchaser (to the extent a seller under a Forward Registration Statement (as defined in Exhibit A)), the officers, directors, agents, partners, members, managers, shareholders, affiliates, employees and investment advisers of
each Purchaser, each person who controls each Purchaser (within the meaning of Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and the officers,
directors, partners, members, managers, shareholders, agents, affiliates, employees and investment advisers of each such controlling person, to the fullest extent permitted by applicable law, from and against any

  
 8 

 
and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable costs of preparation and investigation and reasonable attorneys’ fees) and expenses
(collectively, “Losses”), as incurred, that arise out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in a Forward Registration Statement, any prospectus included in a Forward
Registration Statement or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance of its obligations under this Section 4, except to the extent, but only to
the extent, that such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding a Purchaser furnished in writing to the Company by such Purchaser expressly for use therein. 

The Company shall notify such Purchaser promptly of the institution, threat or assertion of any proceeding arising from or in connection with
the transactions contemplated by this Section 4 of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of an indemnified party and shall
survive the transfer of the Registrable Securities by the Company. 
 (ii)    Each Purchaser shall,
severally and not jointly with any other selling shareholder named in a Forward Registration Statement, indemnify and hold harmless the Company, its directors, officers, agents and employees, each person who controls the Company (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling persons, to the fullest extent permitted by applicable law, from and against all Losses, as
incurred, arising out of or that are based upon any untrue or alleged untrue statement of a material fact contained in a Forward Registration Statement, any prospectus included in a Forward Registration Statement, or any form of prospectus, or in
any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information
regarding such Purchaser furnished in writing to the Company by such Purchaser expressly for use therein. In no event shall the liability of a Purchaser be greater in amount than the dollar amount of the net proceeds received by such Purchaser upon
the sale of the Registrable Securities giving rise to such indemnification obligation. 

5.        Additional Agreements and Acknowledgements of the Purchasers. 

(a)    Trust Account. 

(i)    Each Purchaser hereby acknowledges that it is aware that the Company will establish a trust account
(the “Trust Account”) for the benefit of its public 

  
 9 

 
shareholders upon the IPO Closing. Each Purchaser, for itself and its affiliates, hereby agrees that it has no right, title, interest or claim of any kind in or to any monies held in the Trust
Account, or any other asset of the Company as a result of any liquidation of the Company, except for redemption and liquidation rights, if any, such Purchaser may have in respect of any Public Shares, if any, held by it. 

(ii)    Each Purchaser hereby agrees that it shall have no right of
set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies in, the Trust
Account that it may have now or in the future, except for redemption and liquidation rights, if any, such Purchaser may have in respect of any Public Shares held by it. In the event a Purchaser has any Claim against the Company under this Agreement,
such Purchaser shall pursue such Claim solely against the Company and its assets outside the Trust Account and not against the property or any monies in the Trust Account, except for redemption and liquidation rights, if any, such Purchaser may have
in respect of any Public Shares held by it. 
 (b)    Voting. Each Purchaser hereby agrees that if the Company
seeks shareholder approval of a proposed Business Combination, then in connection with such proposed Business Combination, such Purchaser shall vote any Class A Shares owned by it in favor of any proposed Business Combination. If a Purchaser
fails to vote any Class A Shares it is required to vote hereunder in favor of a proposed Business Combination, such Purchaser hereby grants hereunder to the Company and any representative designated by the Company without further action by such
Purchaser a limited irrevocable power of attorney to effect such vote on behalf of such Purchaser, which power of attorney shall be deemed to be coupled with an interest. 

(c)    No Short Sales. Each Purchaser hereby agrees that neither it, nor any person or entity acting on its behalf
or pursuant to any understanding with it, will engage in any Short Sales with respect to securities of the Company prior to the Business Combination Closing. For purposes of this Section 5, “Short Sales”
shall include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of
business as part of prime brokerage arrangements), forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return basis), each of such foregoing instruments that is naked short, and short sales and other
short transactions through non-U.S. broker dealers or foreign regulated brokers. 

6.        Listing. The Company will use commercially reasonable efforts to effect and
maintain the listing of the Class A Shares and the Redeemable Warrants on the New York Stock Exchange (or another national securities exchange). 

7.        Forward Closing Conditions. 

(a)    The obligation of each Purchaser to purchase the Securities at the Forward Closing under this Agreement shall be
subject to the fulfillment, at or prior to the Forward Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the Purchaser: 

  
 10 

 (i)    (A) With respect to the Forward Closing occurring
on the date of the Business Combination Closing, the Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Securities and (B) with respect to the Forward Closing occurring
prior to the date of the Business Combination Closing, the Company shall not have delivered to each Purchaser a revocation of the Notice with respect to such Forward Purchase; 

(ii)    The Company shall have delivered to such Purchasers a certificate evidencing the Company’s
good standing as a Cayman Islands exempted company, as of a date within ten (10) Business Days of the Forward Closing; 

(iii)    The representations and warranties of the Company set forth in Section 3
of this Agreement shall have been true and correct as of the date hereof and shall be true and correct as of the Forward Closing date, as applicable, with the same effect as though such representations and warranties had been made on and as of such
date (other than any such representation or warranty that is made by its terms as of a specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse
effect on the Company or its ability to consummate the transactions contemplated by this Agreement; 

(iv)    The Company shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Forward Closing; and 

(v)    No order, writ, judgment, injunction, decree, determination, or award shall have been entered by or
with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect, preventing the purchase by the Purchasers of the Securities. 

(b)    The obligation of the Company to sell the Securities at the Forward Closing under this Agreement shall be subject
to the fulfillment, at or prior to the Forward Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by the Company: 

(i)    (A) With respect to the Forward Closing occurring on the date of the Business Combination Closing,
the Business Combination shall be consummated substantially concurrently with, and immediately following, the purchase of the Securities and (B) with respect to the Forward Closing occurring prior to the date of the Business Combination
Closing, Company shall not have delivered to each Purchaser a revocation of the Notice with respect to such Forward Purchase; 

(ii)    The representations and warranties of the Purchasers set forth in
Section 2 of this Agreement shall have been true and correct as of the date hereof and shall be true and correct as of such Forward Closing date, as applicable, with the same effect as though such representations and
warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a specified date, 

  
 11 

 
which shall be true and correct as of such specified date), except where the failure to be so true and correct would not have a material adverse effect on the Purchasers or their ability to
consummate the transactions contemplated by this Agreement; 
 (iii)    The Purchasers shall have
performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchasers at or prior to such Forward Closing; and 

(iv)    No order, writ, judgment, injunction, decree, determination, or award shall have been entered by or
with any governmental, regulatory, or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall be in effect, preventing the purchase by the Purchasers of the Securities. 

8.        Termination. This Agreement may be terminated at any time prior to the Forward
Closing: 
 (a)    by mutual written consent of the Company and the Purchaser; or 

(b)    automatically: 

(i)    if the IPO is not consummated on or prior to December 31, 2020; or 

(ii)    if the Business Combination is not consummated within 24 months from the IPO Closing, unless
extended upon approval of the Company’s shareholders in accordance with the Charter. 
 In the event of any termination of this
Agreement pursuant to this Section 8, any Forward Purchase Price (and interest thereon, if any), if previously paid, and each Purchaser’s funds paid in connection herewith shall be promptly returned to the Purchasers,
the Company shall ensure appropriate instruments are executed to ensure that the any holder of Class A Shares issued in the IPO will have no claim to such funds, and thereafter this Agreement shall forthwith become null and void and have no
effect, without any liability on the part of the Purchasers or the Company and their respective directors, officers, employees, partners, managers, members, or shareholders and all rights and obligations of each of the parties shall cease;
provided, however, that nothing contained in this Section 8 shall relieve either party from liabilities or damages arising out of any fraud or willful breach by such party of any of its representations, warranties,
covenants or agreements contained in this Agreement. 
 9.        General Provisions.

 (a)    Notices. All notices and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile (if any) during normal business hours of the
recipient, and if not sent during normal business hours, then on the recipient’s next Business Day, (c) five (5) Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or
(d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, 

  
 12 

 
specifying next Business Day delivery, with written verification of receipt. All communications sent to the Company shall be sent to: 

TPG Pace Tech Opportunities Corp., 

301 Commerce St., Suite 3300, 

Fort Worth, TX 76102 
 Attention:
Jerry Neugebauer and Michael LaGatta 
 E-mail: officeofthegeneralcounsel@tpg.com 

with a copy to the Company’s counsel at: 

Weil, Gotshal & Manges LLP 

767 Fifth Avenue 
 New York, New
York 10153 
 Attention: Alexander D. Lynch, Esq. 

E-mail: Alex.Lynch@weil.com 

All communications to the Purchasers shall be sent to the Purchasers’ address as set forth on the signature page hereof, or to such e-mail address, facsimile number (if any) or address as subsequently modified by written notice given in accordance with this Section 9(a). 

(b)    No Finder’s Fees. Each of the parties represents that it neither is nor will be obligated for any
finder’s fee or commission in connection with this transaction. Each Purchaser agrees, severally and not jointly, to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a
finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which such Purchaser or its officers, employees or representatives is responsible. The
Company agrees to indemnify and hold harmless the Purchasers from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against
such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

(c)    Adjustments to Notional Amounts. In the event of any change to the capital structure of the Company, whether
dilutive or otherwise, by way of a share dividend or share split, or any other dividend however described, the Securities and the Forward Purchase Price will be adjusted to account for such changes. 

(d)    Survival of Representations and Warranties. All of the representations and warranties contained herein shall
survive the consummation of the transactions contemplated by this Agreement or (subject to Section 9 herein) the termination hereof. 

(e)    Entire Agreement. This Agreement, together with any documents, instruments and writings that are delivered
pursuant hereto or referenced herein, constitute the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements, or representations by or among the parties hereto,
written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. 

  
 13 

 (f)    Successors. All of the terms, agreements, covenants,
representations, warranties, and conditions of this Agreement are binding upon, and inure to the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

(g)    Assignments. Except as otherwise specifically provided herein, no party hereto may assign either this
Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of each other party. 

(h)    Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an
original but all of which together will constitute one and the same instrument. 
 (i)    Headings. The section
headings contained in this Agreement are inserted for convenience only and will not affect in any way the meaning or interpretation of this Agreement. 

(j)    Governing Law. This Agreement, the entire relationship of the parties hereto, and any litigation between the
parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New York, without giving effect to its choice of laws principles. 

(k)    Jurisdiction. The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the
state courts of New York and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to
commence any suit, action or other proceeding arising out of or based upon this Agreement except in state courts of New York or the United States District Court for the Southern District of New York, and (c) hereby waive, and agree not to
assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or
execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

(l)    Waiver of Jury Trial. The parties hereto hereby waive any right to a jury trial in connection with any
litigation pursuant to this Agreement and the transactions contemplated hereby. 
 (m)    Amendments. This
Agreement may not be amended, modified or waived as to any particular provision, except with the prior written consent of the Company and each Purchaser. 

(n)    Severability. The provisions of this Agreement will be deemed severable and the invalidity or
unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any 

  
 14 

 
party hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in accordance with its terms, the parties hereto agree that the
governmental authority, arbitrator, or mediator making such determination will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases, and in its
reduced form, such provision will then be enforceable and will be enforced. 
 (o)    Expenses. Each of the
Company and each Purchaser will bear its own costs and expenses incurred in connection with the performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents, representatives,
financial advisors, legal counsel and accountants. The Company shall be responsible for the fees of its transfer agent, stamp taxes and all The Depository Trust Company fees associated with the issuance of the Securities and the securities issuable
upon conversion or exercise of the Securities. 
 (p)    Construction. The parties hereto have participated
jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof will arise
favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. Any reference to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and regulations
promulgated thereunder, unless the context requires otherwise. The words “include,” “includes,” and “including” will be deemed to be followed by “without limitation.”
Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires. The words “this
Agreement,” “herein,” “hereof,” “hereby,” “hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly
so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect,
the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that
such party hereto is in breach of the first representation, warranty, or covenant. 
 (q)    Waiver. No waiver by
any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder
or affect in any way any rights arising because of any prior or subsequent occurrence. 
 (r)    Confidentiality.
Except as may be required by law, regulation or applicable stock exchange listing requirements, unless and until the transactions contemplated hereby and the terms hereof are publicly announced or otherwise publicly disclosed by the Company, the
parties hereto shall keep confidential and shall not publicly disclose the existence or terms of this Agreement. 

(s)    Specific Performance. Each Purchaser agrees that irreparable damage may occur in the event any provision of
this Agreement was not performed by such Purchaser in 

  
 15 

 
accordance with the terms hereof and that the Company shall be entitled to seek specific performance of the terms hereof, in addition to any other remedy at law or equity. 

[Signature Page Follows] 

  
 16 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement to be
effective as of the date first set forth above. 
  

			
	PURCHASER:
	
	[●]
		
	By:	 	  

		 	Name:
		 	Title:
	
	Address for Notices:
	
	E-mail:
	
	COMPANY:
	
	TPG PACE TECH OPPORTUNITIES CORP.
		
	By:	 	 /s/ Karl Peterson

		 	Name: Karl Peterson
		 	Title: Non-Executive Chairman and Director

 [To be completed by the Company] 

 

			
	Number of Forward Purchase Shares:	  	
		
	Number of Forward Purchase Warrants:	  	
		
	Aggregate Purchase Price for Forward Purchase Securities:	  	$            

  
 [Signature Page to
Forward Purchase Agreement] 

 EXHIBIT A 

REGISTRATION RIGHTS 

1.    The Company shall (i) use commercially reasonable efforts to file within thirty (30) calendar days after
the Business Combination Closing (the “Filing Date”) a registration statement on Form S-3, or if the Company is ineligible to use Form S-3, on Form S-1, for a secondary offering (including any successor registration statement covering the resale of the Registrable Securities a “Forward Registration Statement”) of (x) the Class A
Shares and Redeemable Warrants (and underlying Class A Shares) comprising the Securities, (y) any other equity security of the Company issued or issuable with respect to the securities referred to in clause (x) by way of a share
dividend or share split or by way of a conversion from a warrant, or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization and (z) any other shares or warrants of the Company that the Purchasers
may have purchased in the open market (collectively, the “Registrable Securities”) pursuant to Rule 415 under the Securities Act; (ii) to use commercially reasonable efforts to cause a Forward Registration Statement to be
declared effective under the Securities Act as soon as practicable after the filing thereof but no later than the earlier of (i) the 90th calendar day (or 120th calendar day if the SEC notifies the Company that it will “review” the
Registration Statement) following the Business Combination Closing and (ii) the 10th Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Registration Statement will not be
“reviewed” or will not be subject to further review (such earlier date, the “Effectiveness Date”); provided however, that the Company’s obligation to include the Registrable Securities in the Forward
Registration Statement are contingent upon the Purchaser furnishing in writing to the Company such information regarding the Purchaser, the securities of the Company held by the Purchaser and the intended method of disposition of the Registrable
Securities as shall be reasonably requested by the Company to effect the registration of the Registrable Securities, and the Purchaser shall execute such documents in connection with such registration as the Company may reasonably request that are
customary of a selling stockholder in similar situations, including providing that the Company shall be entitled to postpone and suspend the effectiveness or use of the Forward Registration Statement during any customary blackout or similar period
or as permitted hereunder. The Company shall maintain each Forward Registration Statement in accordance with the terms hereof, and shall prepare and file with the SEC such amendments, including post-effective amendments, and supplements as may be
necessary to keep such Forward Registration Statement continuously effective, available for use and in compliance with the provisions of the Securities Act until such time as there are no longer any Registrable Securities included on such Forward
Registration Statement. In the event the Company files a Forward Registration Statement on Form S-1, the Company shall use its commercially reasonable efforts to convert the Form
S-1 to a Form S-3 as soon as practicable after the Company is eligible to use Form S-3. For purposes of clarification, any
failure by the Company to file the Registration Statement by the Filing Date or to effect such Registration Statement by the Effectiveness Date shall not otherwise relieve the Company of its obligations to file or effect the Registration Statement
as set forth in this Exhibit A. 
 2.    The Company further agrees that, in the event that the Forward
Registration Statement has not been declared effective by the SEC by the Effectiveness Date, (a “Registration Default” and, for purposes of such clauses, the date on which such Registration Default occurs, a

  
 Exhibit A-1 

 
“Default Date”), then in addition to any other rights the Purchaser may have hereunder or under applicable law, on each such Default Date and on each monthly anniversary of each such
Default Date (if the Registration Default shall not have been cured by such date) until the Registration Default is cured, the Company shall pay to each Purchaser, an amount in cash, as partial liquidated damages and not as a penalty
(“Liquidated Damages”), equal to 0.5% of the aggregate Forward Purchase Price paid by the Purchaser pursuant to this Agreement for any Registrable Securities held by the Purchaser on the Default Date; provided, however, that if the
Purchaser fails to provide the Company with any information requested by the Company that is required to be provided in such Forward Registration Statement with respect to the Purchaser as set forth herein, then, for purposes of this Exhibit
A, the Filing Date or Effectiveness Date, as applicable, for a Forward Registration Statement with respect to the Purchaser shall be extended until two (2) Business Days following the date of receipt by the Company of such required
information from the Purchaser; and in no event shall the Company be required hereunder to pay to the Purchaser pursuant to this Agreement an aggregate amount that exceeds 5.0% of the aggregate Forward Purchase Price paid by the Purchaser for its
Registrable Securities. The Liquidated Damages pursuant to the terms hereof shall apply on a daily pro-rata basis for any portion of a month prior to the cure of a Registration Default, except in the case of
the first Default Date. The Company shall deliver the cash payment to the Purchaser with respect to any Liquidated Damages by the fifth Business Day after the date payable. If the Company fails to pay said cash payment to the Purchaser in full by
the fifth Business Day after the date payable, the Company will pay interest thereon at a rate of 5.0% per annum (or such lesser maximum amount that is permitted to be paid by applicable law, and calculated on the basis of a year consisting of 360
days) to such Purchaser, accruing daily from the date such Liquidated Damages are due until such amounts, plus all such interest thereon, are paid in full. Notwithstanding the foregoing, nothing shall preclude any Purchaser from pursuing or
obtaining any available remedies at law, specific performance or other equitable relief with respect to this Exhibit A in accordance with applicable law. The parties agree that notwithstanding anything to the contrary herein, no Liquidated
Damages shall be payable to the Purchaser with respect to any period during which all of such Purchaser’s Registrable Securities may be sold by the Purchaser without volume or manner of sale restrictions under Rule 144 and the Company is in
compliance with the current public information requirements under Rule 144(c)(1) (or Rule 144(i)(2), if applicable). Notwithstanding the foregoing, any failure by the Company to have the Forward Registration Statement declared effective by the SEC
by the Effectiveness Date as a result of the unavailability of Form S-3 for the registration of the Registrable Securities will not result in a Registration Default or the Company being obligated to pay or any
Purchaser being entitled to receive any liquidated damages. 
 3.    In the case of the registration, qualification,
exemption or compliance effected by the Company pursuant to this Agreement, the Company shall, upon reasonable request, inform the Purchaser as to the status of such registration, qualification, exemption and compliance. At its expense the Company
shall: 
 (i) except for such times as the Company is permitted hereunder to suspend the use of the prospectus forming part
of a Forward Registration Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which the Company determines to obtain, continuously effective with
respect to the Purchaser, and to keep the applicable 

  
 Exhibit A-2 

 
Forward Registration Statement or any subsequent shelf Forward Registration Statement free of any material misstatements or omissions, until the earlier of the following: (i) the Purchaser
ceases to hold any Registrable Securities or (ii) the date all Registrable Securities held by the Purchaser may be sold without restriction under Rule 144, including without limitation, any volume and manner of sale restrictions which may be
applicable to affiliates under Rule 144 and without the requirement for the Company to be in compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if applicable), and (iii) three years from the
Effective Date of the Forward Registration Statement. The period of time during which the Company is required hereunder to keep a Forward Registration Statement effective is referred to herein as the “Registration Period”; 

(ii) advise the Purchaser within five (5) Business Days: 

(1) when a Forward Registration Statement or any amendment thereto has been filed with the SEC and when such Forward Registration Statement or
any post-effective amendment thereto has become effective; 
 (2) of any request by the SEC for amendments or supplements to any Forward
Registration Statement or the prospectus included therein or for additional information; 
 (3) of the issuance by the SEC of any stop order
suspending the effectiveness of any Forward Registration Statement or the initiation of any proceedings for such purpose; 
 (4) of the
receipt by the Company of any notification with respect to the suspension of the qualification of the Registrable Securities included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and 

(5) subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes in any
Forward Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a
prospectus, in the light of the circumstances under which they were made) not misleading. 
 (iii) use its commercially
reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Forward Registration Statement as soon as reasonably practicable; 

(iv) upon the occurrence of any event contemplated above, except for such times as the Company is permitted hereunder to
suspend, and has suspended, the use of a prospectus forming part of a Forward Registration Statement, the Company shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such Forward
Registration Statement or a supplement to the 

  
 Exhibit A-3 

 
related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Securities included therein, such prospectus will not include any untrue
statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

(v) use its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or
market, if any, on which the Existing Parent Class A Shares issued by the Company have been listed; and 
 (vi) use its
commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated hereby and to enable the Purchaser to sell the Registrable Securities under Rule 144. 

4.    Notwithstanding anything to the contrary in this Agreement, the Company shall be entitled to delay or postpone the
effectiveness of the Forward Registration Statement, and from time to time to require the Purchaser not to sell under the Forward Registration Statement or to suspend the effectiveness thereof, if the negotiation or consummation of a transaction by
the Company or its subsidiaries is pending or an event has occurred, which negotiation, consummation or event the Company’s Board of Directors reasonably believes, upon the advice of legal counsel, would require additional disclosure by the
Company in the Forward Registration Statement of material information that the Company has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Forward Registration
Statement would be expected, in the reasonable determination of the Company’s Board of Directors, upon the advice of legal counsel, to cause the Forward Registration Statement to fail to comply with applicable disclosure requirements (each such
circumstance, a “Suspension Event”); provided, however, that the Company may not delay or suspend the Forward Registration Statement on more than two occasions or for more than sixty (60) consecutive calendar
days, or more than ninety (90) total calendar days, in each case during any twelve-month period. Upon receipt of any written notice from the Company of the happening of any Suspension Event during the period that the Forward Registration
Statement is effective or if as a result of a Suspension Event the Forward Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, the Purchaser agrees that (i) it will immediately discontinue offers and sales of the Registrable
Securities under the Forward Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule 144) until the Purchaser receives copies of a supplemental or amended prospectus (which the Company agrees to promptly
prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective or unless otherwise notified by the Company that it may resume such offers and sales, and
(ii) it will maintain the confidentiality of any information included in such written notice delivered by the Company unless otherwise required by law or subpoena. If so directed by the Company, the Purchaser will deliver to the Company or, in
the Purchaser’s sole discretion destroy, all copies of the prospectus covering the Registrable Securities in the Purchaser’s possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering
the Registrable Securities shall not apply (i) to the extent the Purchaser is required to retain a copy of 

  
 Exhibit A-4 

 
such prospectus (a) in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (b) in accordance with a bona fide pre-existing document retention policy or (ii) to copies stored electronically on archival servers as a result of automatic data back-up. 

5.    The Purchaser may deliver written notice (including via email) (an
“Opt-Out Notice”) to the Company requesting that the Purchaser not receive notices from the Company otherwise required by this Section 5; provided,
however, that the Purchaser may later revoke any such Opt-Out Notice in writing. Following receipt of an Opt-Out Notice from the Purchaser (unless subsequently
revoked), (i) the Company shall not deliver any such notices to the Purchaser and the Purchaser shall no longer be entitled to the rights associated with any such notice and (ii) each time prior to the Purchaser’s intended use of an
effective Forward Registration Statement, the Purchaser will notify the Company in writing at least two (2) Business Days in advance of such intended use, and if a notice of a Suspension Event was previously delivered (or would have been
delivered but for the provisions of this Section 5) and the related suspension period remains in effect, the Company will so notify the Purchaser, within one (1) Business Day of the Purchaser’s notification to the
Company, by delivering to the Purchaser a copy of such previous notice of Suspension Event, and thereafter will provide the Purchaser with the related notice of the conclusion of such Suspension Event immediately upon its availability. 

  
 Exhibit A-5EX-10.1

 Exhibit 10.1 

Certain information contained in this document, identified by [***], has been redacted because it is both (i) not material and (ii) would likely cause
competitive harm to the Registrant if publicly disclosed. 
  
  

 
 AND 

OPTHEA 
 Commercial
License Agreement 
 Date: October 28, 2013 

  
 Selexis 2013 

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 This Commercial License Agreement (this “Agreement”) is made effective on October 28,
2013 (the “Effective Date”) 
 by and between 

Selexis SA, a company incorporated under the laws of Switzerland, with its registered office at [***], Geneva, Switzerland
(“SELEXIS”) 
 and 

OPTHEA PTY LTD, a company incorporated under the laws of Australia, with its registered office at Level 4, 650 Chapel Street, South Yarra,
Victoria 3141, Australia (“COMPANY”) 
 (SELEXIS and COMPANY, collectively the “PARTIES” and, individually, a
“PARTY”) 
 Preamble 
  

	A.	 WHEREAS, COMPANY is a biopharmaceutical company engaged in the research, development,
manufacturing and sale of biopharmaceutical products; 

  

	B.	 WHEREAS, SELEXIS is a biotechnology company engaged in the development and sale of recombinant
cell lines based on the SELEXIS Technology; 

  

	C.	 WHEREAS, SELEXIS is the owner of certain Confidential Information, the SELEXIS Know-How and the SELEXIS Patent Rights; 

  

	D.	 WHEREAS, pursuant to a services agreement between the PARTIES dated November 26, 2012 (the
“Services Agreement”) SELEXIS has developed certain recombinant cell line(s) for COMPANY using the SELEXIS Technology and COMPANY has evaluated such cell Line(s); and 

 

	E.	 WHEREAS, SELEXIS is willing to grant COMPANY, and COMPANY is willing to receive from SELEXIS, a
license to the SELEXIS Know-How and the SELEXIS Patent Rights with respect to the recombinant cell lines, on the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, the PARTIES agree as follows: 

  

					
	Date: October 28, 2013	 	2 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.	 Definitions 

In addition to the terms defined above, the following terms, whether used in the singular or plural, shall have the following meanings as used in this
Agreement, unless otherwise specifically indicated: 
  

	1.1.	 “Affiliate” shall mean any Person that, as of the Effective Date, directly or
indirectly, controls, is controlled by, or is under common control with the relevant Person. For the purposes of this definition only, “control” shall mean the possession, directly or indirectly, of the power to cause the
direction of the management and policies of a Person, whether through ownership of voting securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such Control exists. 

 

	1.2.	 “BLA” shall mean a Biologic License Application for the Final Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. 

  

	1.3.	 “Calendar Quarter” shall mean, for each Calendar Year, each of the three month periods
ending March 31, June 30, September 30 and December 31 respectively. 

  

	1.4.	 “Calendar Year” shall mean the period commencing on January 1 and ending twelve
(12) consecutive calendar months later on December 31. 

  

	1.5.	 “Cell Line” shall mean a mammalian cell line that is developed using the SELEXIS
Technology. Cell Line shall include, without limitation, any COMPANY Cell Line(s). 

  

	1.6.	 “Clinical Trials” shall mean human studies designed to measure the safety and/or
efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. 

  

	1.7.	 “Collaboration Partner” shall mean a Third Party with which COMPANY collaborates on the
development of the production process and/or commercialization of a Licensed Product or Final Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product.

  

	1.8.	 “Combination Product Adjustment” shall mean the adjustment of: Net Sales for any
combination product done by multiplying actual Net Sales of such combination product by the fraction A/(A + B) where [***], if sold separately, and [***], if sold separately. If, on a
country-by-country basis, the other active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual
Net Sales of the combination product in such country by the fraction A/C where [***], if sold separately, in such country and [***]. 

  

	1.9.	 “Commercial License” shall have the meaning set out in Article 2.1.

  

	1.10.	 “Commercial License Option” shall mean the option granted to Company in the Services
Agreement to obtain a non-exclusive commercial license. 

  

					
	Date: October 28, 2013	 	3 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.11.	 “COMPANY Technology” shall mean any Technology owned or controlled by COMPANY,
including, without limitation, any such Technology related to Licensed or Final Product, but excluding any SELEXIS Technology related thereto. 

  

	1.12.	 “COMPANY Cell Line” shall mean the mammalian cell line developed by SELEXIS and
provided to COMPANY pursuant to the Services Agreement and any progeny or derivatives thereof. A Cell Line which has been [***] shall be described as such in this Agreement. 

 

	1.13.	 “Confidential Information” shall mean any technical and business information pertaining
to materials and production techniques, products, processes and services, including without limitation physical working models and samples of the products, research, development, patentable and unpatentable inventions, manufacturing, purchasing and
product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants, blueprints, technical
information, trade secrets or know-how or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form, written, oral, graphic,
pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium. Confidential Information disclosed in any tangible format will be labeled “Confidential” or words to similar
effect, and all non-tangible disclosures will be declared to be “Confidential” or words to similar effect at the time of disclosure. Confidential Information shall include any and all material and
data created by the receiving party based on, containing or otherwise reflecting Confidential Information. Confidential Information shall also include any such information or documents which may be disclosed hereunder which the disclosing party
received in confidence from a Third Party. 

  

	1.14.	 “Contract Manufacturing Organization” shall mean an entity of which at least fifty
percent (50%) of the business is directed toward the provision of services or products for non-affiliate third parties. 

 

	1.15.	 “Contractor” shall mean a Third Party contractor who: (i) develops the production
process for Licensed Products or Final Products by or on behalf of COMPANY or (ii) manufactures and supplies Licensed Products or Final Products by using such production process by or on behalf of Company. 

 

	1.16.	 “Default” shall have the meaning set out in Article 9.2. 

 

	1.17.	 “Defaulting Party” shall have the meaning set out in Article 9.2.

  

	1.18.	 “Deliverables” shall mean the reports and other data delivered to COMPANY
pursuant to the Services Agreement, excluding the COMPANY Cell Line. 

  

					
	Date: October 28, 2013	 	4 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.19.	 “FDA” shall mean the United States Food and Drug Administration, or any successor
agency. 

  

	1.20.	 “Final Product” shall mean any pharmaceutical preparation in final form
containing any Licensed Products for sale by prescription, over-the-counter or any other method, in any dosage form, formulation, presentation, line extension or package
configurations, including without limitation such Product in development where the context so requires in this Agreement. 

  

	1.21.	 “First Commercial Sale” shall mean, with respect to any Final Product in any country,
the first sale of such Final Product for use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Final Product has been obtained in such country. For the avoidance of
doubt, sales prior to receipt of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”, “named
patient sales” and “compassionate use sales”, shall not be construed as a First Commercial Sale. 

  

	1.22.	 “Force Majeure” shall mean conditions beyond the control of a PARTY, including without
limitation, an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by fire,
earthquake, storm or the like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence and prudence that would be reasonably and ordinarily expected from a skilled
and experienced person engaged in the same type of undertaking under the same or similar circumstances). 

  

	1.23.	 “IND” shall mean an Investigational New Drug Application for the Product filed with the
FDA or any comparable filing made with a Regulatory Authority in another country. 

  

	1.24.	 “Insolvent Party” shall have the meaning set out in Article 9.3. 

 

	1.25.	 “Invention” shall mean any invention, idea, innovation, enhancement, improvement or
feature, whether or not patentable or registrable, together with any intellectual property rights relating thereto (including without limitation the Patent Rights and rights to confidentiality and proprietary information). 

 

	1.26.	 “Know-How” shall mean information in whatever
form, tangible or intangible and on whatever medium, including without limitation, information and materials relating to Inventions and other know-how, trade secrets, data (including without limitation all
data from pre-clinical and clinical studies and other studies intended for regulatory submission), results, formulae, DNA and amino acid sequence information and developments. 

 

	1.27.	 “Licensed Field of Use” shall mean all uses of a Licensed and/or Final Product.

  

	1.28.	 “Licensed Product” shall mean the recombinant protein listed in Exhibit 2.

  

					
	Date: October 28, 2013	 	5 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.29.	 “Losses” shall mean all and any liability, damage, loss or expense.

  

	1.30.	 “Net Sales” shall mean the amount collected by COMPANY, its Affiliates and/or its
sublicensees on account of sales of Final Product to Third Parties in the Territory, less the following deductions: 

  

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; 

  

	 	(v)	 [***]; and 

  

	 	(vi)	 in the event that a Final Product is sold in any country in the form of a combination product containing one or
more other therapeutically active ingredients, the Net Sales for any such Final Product shall be computed using the Combination Product Adjustment for such country. 

 

	1.31.	 “Non-Defaulting Party” shall have the meaning
set out in Article 9.2. 

  

	1.32.	 “Notice of Default” shall have the meaning set out in Article 9.2.

  

	1.33.	 “Patent Rights” shall mean any and all of the following: (i) patent applications
(including without limitation provisional patent applications) and patents (including without limitation the inventor’s certificates); (ii) any substitution, extension (including without limitation patent term extensions and supplementary
protection certificates), registration, confirmation, reissue, continuation, divisional, continuation-in-part, re-examination,
renewal, patent of addition or the like thereof or thereto; (iii) any foreign counterparts of any of the foregoing; and (iv) any utility model applications and utility models (whether or not corresponding to any of the foregoing).

  

	1.34.	 “Person” shall mean an individual, a partnership, a joint venture, a corporation, a
limited liability company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual, fiduciary or other capacity. 

 

	1.35.	 “Phase I Clinical Trial” shall mean a Clinical Trial conducted in humans which is
principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have commenced when the first patient in the study has been treated. Phase I shall be deemed to
have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the
primary endpoint. 

  

					
	Date: October 28, 2013	 	6 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.36.	 “Phase II Clinical
Trial” shall mean a Clinical Trial conducted in humans in which the primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being
studied. Phase II shall be deemed to have commenced when the first patient in the study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial
as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary endpoint. 

  

	1.37.	 “Phase III Clinical Trial” shall mean a Clinical Trial conducted in humans in which the
primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have commenced when the first patient in the study has been treated. Phase III shall be deemed to have
completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary
endpoint. 

  

	1.38.	 “Price and Reimbursement Approval” shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its reimbursement
level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. 

  

	1.39.	 “Regulatory Approval” shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or sale of a Product or conduct of Clinical
Trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. 

  

	1.40.	 “Regulatory Authority” shall mean (i) the FDA or (ii) any and all
governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world.

  

	1.41.	 “Royalty Term” shall mean with respect to each Final Product sold in a particular
country, the period beginning on the date of the First Commercial Sale in such country and terminating on the expiration of the last-to-expire or lapse of any Valid Claims in such country covering the Licensed Product, the Final Product, the Company
Cell Line, or any other Cell Line used to produce Licensed Product, or the development, use, or manufacture of any of the foregoing. In no event shall the Royalty Term exceed the 22nd of October
2024. 

  

	1.42.	 “SELEXIS Know-How” shall mean SELEXIS’
Confidential Information and Know-How owned, controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License relating to,
without limitation, the construction and development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter during the Term. 

 

	1.43.	 “SELEXIS Materials” shall mean the materials provided by SELEXIS to COMPANY under this
Agreement and all modifications and improvements thereof made by SELEXIS during the Term, if any. SELEXIS Materials excludes the Cell Lines. 

  

					
	Date: October 28, 2013	 	7 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	1.44.	 “SELEXIS Patent Rights” shall mean Patent Rights which: (i) are owned or
controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License (ii) are necessary or useful for the use of SELEXIS Materials or the construction, development
and use of Cell Lines and (iii) are existing as of the Effective Date or obtained thereafter during the Term. Without limiting the generality this Article, the SELEXIS Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.

  

	1.45.	 “SELEXIS Technology” shall mean the SELEXIS Patent Rights, the SELEXIS Know-How and the SELEXIS Materials. 

  

	1.46.	 “Tax Authority” shall mean the relevant governing tax authority as defined in Article
4.2. 

  

	1.47.	 “Taxes” shall mean all excises, taxes and duties with the exception of VAT.

  

	1.48.	 “Technology” shall mean all inventions (whether or not patentable or patented) and
intellectual property rights therein, including without limitation, patents, patent applications, know-how, trade secrets, copyrights, trademarks, designs, concepts, registered and unregistered design rights,
data, work product, results, reports, improvements, business and research plans, analytic methods and results, experimental methods and results, manufacturing processes, developments, technologies, technical information, composites of genes and gene
constructs, cell lines, manuals, standard operating procedures, instructions and specifications. 

  

	1.49.	 “Term” shall have the meaning set out in Article 9.1. 

 

	1.50.	 “Territory” shall mean the entire world. 

 

	1.51.	 “Third Party” shall mean a Person other than SELEXIS, COMPANY or an Affiliate of
SELEXIS or COMPANY. 

  

	1.52.	 “Transferee” shall have the meaning set out in Article 2.3. 

 

	1.53.	 “Valid Claim” shall mean any issued or granted claim of the SELEXIS Patent Rights that
has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not been
disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

 

	1.54.	 “VAT” shall mean value added tax and any other similar turnover, sales or purchase, tax
or duty levied by any other jurisdiction whether central, regional or local. 

  

					
	Date: October 28, 2013	 	8 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	2.	 Commercial Licenses 

 

	2.1.	 Commercial Licenses. Subject to COMPANY’s compliance with the other terms and conditions of this
Agreement (including, without limitation, payment by COMPANY of the amounts provided for below in accordance with the payment schedule and terms provided for below), SELEXIS hereby grants to COMPANY a
non-exclusive worldwide license under the SELEXIS Patent Rights and SELEXIS Know-How, in the Territory, with the limited right to sublicense in accordance with Article
2.2, to use Cell Lines, Deliverables and SELEXIS Materials for the manufacture of Licensed and/or Final Products, and to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Licensed Field of
Use, including, without limitation, the use of Licensed and/or Final Products in Clinical Trials (the “Commercial License”). 

  

	2.2.	 Sublicenses. Subject to the provisions of this Article 2.2, COMPANY shall be entitled to grant
sublicenses to the rights granted under the Commercial License to any one or more third parties (the “Sublicensees”) provided always: 

  

	 	2.2.1.	 Any sublicense granted under this Agreement shall be expressly subject and subordinate to the terms of this
Agreement and it shall be COMPANY’s responsibility to ensure strict adherence by any Sublicensee to the terms and conditions of this Agreement. 

  

	 	2.2.2.	 Any Sublicensee shall not, by virtue of this Agreement, be granted any right or licence, either express or
implied, under any SELEXIS Know-how and/or SELEXIS Patent Rights to use COMPANY Cell Lines, SELEXIS Materials and/or SELEXIS Patent Rights other than for the purposes of the manufacture, use, offer for sale,
sale, import and other exploitation of Licensed and/or Final Products in the Field. 

  

	 	2.2.3.	 COMPANY will notify SELEXIS in writing of any such sublicense within [***] following the grant thereof, and
[***]. 

  

	 	2.2.4.	 Notwithstanding the above, COMPANY is and remains fully liable and responsible for any breach of this Agreement
committed or any Losses caused by any Sublicensee, or any other Third Party or Affiliate to whom the Cell Lines, Deliverables, SELEXIS Materials and the SELEXIS Know-How or parts thereof are made available
under any such sublicense. 

  

	2.3.	 Transfer of SELEXIS Materials. COMPANY shall not transfer the Cell Lines, Deliverables, SELEXIS
Materials or SELEXIS Know-How to any Third Party, except that during and for the Term only, COMPANY may transfer Cell Lines, Deliverables, SELEXIS Materials and SELEXIS
Know-How to Contractors or 

  

					
	Date: October 28, 2013	 	9 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
Collaboration Partners (the “Transferees”) solely for their use in connection with the development of a production process for Licensed and/or Final Product, the manufacturing of
Licensed and/or Final Product for sale or distribution of Final Product in the Licensed Field of Use, or, the commercialization of Licensed and/or Final Product in the Licensed Field of Use, with, for or on behalf of, COMPANY. If COMPANY makes any
such transfer, it shall notify SELEXIS within [***] of any such transfer and report the name and address of any Transferee together with confirmation that the Transferee has agreed in writing to adhere to the confidentiality obligations and use
restrictions set out in this Agreement. 

 For the avoidance of doubt, upon expiration of the last Royalty Term, the Commercial
License granted to COMPANY in Article 2.1 (and the sublicense and transfer rights as set forth in Articles 2.2 and 2.3) shall become perpetual and royalty-free. 
  

	2.4.	 Sale of Licensed Product. If COMPANY (itself or in cooperation with one or more Third Parties) wishes to
sell or otherwise transfer Licensed Product to any Third Party in a form other than as a Final Product, it may do so subject to the following. (a) Such Licensed Product may only be sold or transferred to one or more Third Party(ies) for use in
Clinical Trials, for further research and/or development and/or for formulation for ultimate sale in the Licensed Field of Use as Final Product; (b) Any sale for financial consideration of Licensed Product in a form other than as a Final
Product will be deemed a “Net Sale” of Final Product and Royalty Payments will be due on such sale of Licensed Product in accordance with Article 3.1.3 as if the Licensed Product were Final Product; and (c) All sales of Final Product
incorporating such Licensed Product will be deemed “Net Sales” of a Sublicensee for purposes of this Agreement and will be subject to payment by COMPANY of the royalties set forth in Article 3.1.3, and will trigger payment of the
milestones set forth in Article 3.1.2 if a Final Product produced by such a Third Party is the first Final Product to reach the appropriate milestone trigger point. COMPANY will ensure that sufficient records are kept by COMPANY or available to it
to document the Net Sales of Licensed and/or Final Products to determine the amounts due to SELEXIS under Article 3. 

  

	3.	 Consideration 

 

	3.1.	 Payments. In consideration of the Commercial License granted to COMPANY pursuant to Article 2.1, and in
consideration of the right to sublicense the rights granted in Article 2.1 pursuant to Article 2.2, COMPANY shall pay SELEXIS as follows: 

  

	 	3.1.1.	 Commercial License Execution Payment. COMPANY shall pay SELEXIS a
one-time fee of thirty five thousand Swiss Francs (CHF 35,000), due upon execution of this Agreement. 

  

					
	Date: October 28, 2013	 	10 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	3.1.2.	 Commercial License Milestone Payments. COMPANY shall make the following milestone payments to SELEXIS
with respect to the first occurrence of each such milestone event for each Licensed Product: 

  

	 	3.1.2.1    [***];	 

  

	 	3.1.2.2    [***];	 

  

	 	3.1.2.3    [***];  and	 

  

	 	3.1.2.4    [***].	 

  

	 	3.1.3.	 Commercial License Royalty Payments: In addition to the milestone payments under Article 3.1.2, during
the Royalty Term COMPANY shall pay SELEXIS on a Final Product-by-Final Product (including Products deemed Final Products in accordance with Article 2.4, parts
(b) and (c)) and country-by-country basis a royalty of [***] of Net Sales of all Final Products sold worldwide, where said Final Products have been produced from a
Cell Line [***]. If Final Products have been produced from a Cell Line [***], then the royalty rate shall be [***]. Where royalties are due for the sale of Final Products directly by COMPANY such royalties shall be paid for each Calendar Quarter
within [***] of the end of that Calendar Quarter. Where royalties are due for the sales of Final Product by a Sublicensee, payment shall be made within [***] of the end of that Calendar Quarter. For the avoidance of doubt, no royalty payments shall
be due for a Final Product in a specific country after the Royalty Term has expired for such Final Product in such country. Where royalties are no longer due in accordance with the foregoing, the Commercial License granted to COMPANY under this
Agreement shall become perpetual, irrevocable, fully paid up and royalty free with respect to such Licensed and Final Product in such country. At any time during the Term, SELEXIS and COMPANY may agree to remove the royalty in its entirety or in
part in exchange for payment(s) as negotiated. 

  

	3.2.	 Mechanism of Payment. The payments due to SELEXIS under this Agreement shall be made by wire transfer or
electronic fund transfer to the credit and account of SELEXIS as follows: 

 Bank Name :    [***] 

Account:           [***] 

To:                    Selexis S.A. 

                       
   [***] 
  

	3.3.	 Payment Terms. Except with respect to royalties due pursuant to Article 3.1.3, COMPANY shall make
payments due to SELEXIS under this Agreement at the latest [***] after receipt of invoice. All fees and payments, including without limitation under Article 3.1.3, do not include any applicable VAT or Taxes. 

  

					
	Date: October 28, 2013	 	11 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	3.4.	 Records. COMPANY and its Affiliates and Sublicensees shall keep true accounts of Net Sales of Final
Products and COMPANY shall deliver to SELEXIS at the same time as the payments due under Article 3.1.3. a written account, including quantities of Net Sales of each such Final Product, broken down on a country-by-country basis with respect to those payments. SELEXIS is entitled to have such accounts audited by an independent expert of its choice. Such independent expert shall be bound by confidentiality
terms at least as restrictive as the terms of Article 8 and shall be authorized to disclose to SELEXIS only the results of its audit. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be
borne by SELEXIS unless the audit shows that COMPANY underpaid SELEXIS by [***] of the amounts due in which case the cost of the audit shall be borne by COMPANY. 

 

	3.5.	 Single Royalty and Milestone. For Final Products covered by more than one SELEXIS Patent Rights, COMPANY
will make one payment to SELEXIS for royalties on any unit of Final Product sold by COMPANY or Sublicensees, irrespective of how many SELEXIS Patent Rights may cover such Final Product. Each milestone described in Article 3 shall be payable only
once in relation to each Licensed Product, irrespective of the number of Final Products which incorporate that Licensed Product and undergo the events triggering the payment. All fees and payments, including without limitation under Article 3.1, do
not include any applicable VAT or Taxes. 

  

	4.	 Taxes 

  

	4.1.	 General. All Taxes levied on account of any payment made by COMPANY to SELEXIS pursuant to this
Agreement (other than Taxes on income, gains or profits levied against SELEXIS by any competent Swiss tax authority) will be the responsibility of, and shall be paid by, COMPANY pursuant to Article 3. 

 

	4.2.	 Character of Payments. The PARTIES agree that, for purposes of determining the applicability of any
Taxes, the payments to be made under this Agreement constitute payments for tangible property and license of intellectual property. However, in the event that the governing tax authority (the “Tax Authority”) qualifies differently
such payment, any additional taxes that may be applied (including without limitation any interest and penalties that may be unpaid) shall be paid by COMPANY. 

 

	4.3.	 Withholding by COMPANY. 

 

	 	4.3.1.	 All payments by COMPANY hereunder shall be made in full without any deduction or withholding whatsoever and
free and clear of and without any deduction or withholding for or on account of any Taxes, except to the extent that any such deduction or withholding is required by law in effect at the time of payment. If any such deductions or withholdings must
be made from any amounts payable or paid by COMPANY, COMPANY shall [***]. 

  

					
	Date: October 28, 2013	 	12 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	4.3.2.	 Each PARTY shall execute and deliver such documents, deeds and other papers and take such further actions as
may be reasonably required to lawfully enable SELEXIS and COMPANY or their respective Affiliates or Sublicensees to mitigate withholding taxes, such as take advantage of any applicable legal provision or any double taxation treaties, for the purpose
of assigning to SELEXIS full tax credit for amounts deducted or withheld by COMPANY pursuant to Article 4.3.1. 

  

	5.	 Intellectual Property 

 

	5.1.	 Ownership. Each PARTY shall retain all right, title and interest in and to its Inventions and Know-How which exist on the Effective Date or which are thereafter developed independently of the performance of this Agreement. 

 

	5.2.	 COMPANY and SELEXIS Inventions. Any Invention developed hereunder by or for either Party, solely or
jointly with the other PARTY or any Affiliate or agent thereof, shall belong exclusively (i) to COMPANY, to the extent [***] (“COMPANY Invention”); or (ii) to SELEXIS, to the extent [***] (“SELEXIS
Invention”). Any SELEXIS Inventions shall be included within the scope of the SELEXIS Technology licensed to COMPANY under this Agreement as provided for in Article 5.5. Notwithstanding the foregoing, such ownership shall not be construed
to transfer to either PARTY ownership of or any license or other rights in or to any of such PARTY’s underlying Technology which may be included or embodied therein, or useful or necessary to use in connection with exploiting such Invention.

  

	5.3.	 Other Inventions. Except as set forth in Article 5.2, any other Invention developed hereunder solely by
COMPANY shall be COMPANY’s sole property and any other Invention developed hereunder solely by SELEXIS shall be SELEXIS’ sole property. The PARTIES do not anticipate that there will be any jointly developed Inventions hereunder, but if
there are any other such jointly developed Inventions which do not relate to either the SELEXIS Technology or the COMPANY Technology, such Inventions shall be owned jointly by COMPANY and SELEXIS (“Joint Inventions”). In the event
any such Joint Inventions arise, the PARTIES will use commercially reasonable efforts to cooperate to protect and/or exploit such Joint Inventions, including, without limitation, by sharing in costs incurred with protection of such Joint Inventions
and sharing in revenues generated by the use or sublicense of the Joint Inventions. 

  

	5.4.	 Notification. Each PARTY shall promptly notify the other PARTY of any Invention arising in connection
with this Agreement provided that COMPANY has no obligation to notify SELEXIS with respect to any COMPANY Inventions developed solely by COMPANY. 

  

					
	Date: October 28, 2013	 	13 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	5.5.	 Improvements. In the event SELEXIS possesses, acquires, creates or is licensed (with the right to grant
a sublicense consistent with the terms of the Commercial License) any improvements to the SELEXIS Technology which are necessary or useful for COMPANY to use in connection with the use of the Cell Lines as licensed hereunder, such improvements shall
automatically be included in the SELEXIS Patent Rights and/or the SELEXIS Know-How and thereby disclosed and licensed at no extra cost to COMPANY in accordance with this Agreement; provided, however, that any
rights granted by the foregoing will be subject to COMPANY’s compliance with any bona fide obligations owed to Third Parties (with respect to which SELEXIS has notified COMPANY), including, without limitation, and royalty obligations owed to
Third Parties. 

  

	5.6.	 Third Party Patent Rights. SELEXIS covenants that if SELEXIS becomes aware that COMPANY’s use of
the SELEXIS Technology in accordance with the terms hereunder would or would likely infringe any Third Party proprietary rights, SELEXIS shall use its reasonable commercial efforts to resolve such potential infringement at SELEXIS’ cost to
ensure COMPANY’s freedom to continue to exercise the licenses granted under this Agreement, including without limitation by using its reasonable commercial efforts to obtain a license from the Third Party owner of the proprietary rights which
entitles SELEXIS to continue to grant the rights to COMPANY as provided for herein. Should such efforts not be successful, SELEXIS shall inform COMPANY in writing and thereafter the Parties will discuss the matter in good faith for a period not to
exceed [***]. Thereafter [***], save that SELEXIS shall not have such right if COMPANY agrees to [***]. If COMPANY [***] and if COMPANY [***] relating to COMPANY’s permitted use of the SELEXIS Technology hereunder, then COMPANY may [deduct any
royalties actually paid to such Third Party] to the extent related to the use of the SELEXIS Technology [***]; provided that in no event shall the [***] of the royalty amount that would have otherwise been payable for such Final Product]. The
obligations set forth in this Article relate solely to Third Party rights related specifically and solely to the SELEXIS Technology licensed hereunder, and do not apply with respect to any other technology or materials used by COMPANY at its
discretion in connection with its exercise of the license rights granted hereunder, and specifically exclude any such Third Party rights to the extent relating to the Licensed Product(s) produced by any Cell Lines hereunder. 

 

	5.7.	 Enforcement of SELEXIS Patent Rights. If, during the Term, either PARTY becomes aware of any
infringement or potential infringement of the SELEXIS Technology it shall promptly notify the other PARTY in writing and the PARTIES shall consult with each other to decide the best way to respond to such infringement or misuse, provided that
SELEXIS shall remain free to take any action as it deems fit in its sole discretion. 

  

	5.8.	 COMPANY Publications. COMPANY shall have the unrestricted right to publish or otherwise disclose the
results and data obtained by the practice of the SELEXIS Technology in accordance with the terms hereof, provided such publication or disclosure does not include any Confidential Information of SELEXIS. The name of SELEXIS shall be given proper
recognition in such publication(s) as scientifically appropriate. 

  

					
	Date: October 28, 2013	 	14 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	5.9.	 Further Assurance. Each PARTY agrees to execute and do all things at the cost of the other PARTY (if not
specifically agreed otherwise) as the other PARTY may reasonably require to give that other PARTY the full benefit of the provisions of this Article 5. 

  

	6.	 Representations, Warranties, and Covenants 

 

	6.1.	 General. Except for the representations, warranties and covenants contained in Article 5.6 or this
Article 6, the PARTIES do not make any other representations, nor give any other warranties, express or implied, nor undertake to any other covenants. The PARTIES expressly exclude any and all other representations, warranties and covenants.

  

	6.2.	 Representations and Warranties by the PARTIES. Each PARTY hereby represents and warrants to the other
PARTY that: 

  

	 	6.2.1.	 Corporate Power. It is duly organized and validly existing under the laws of the state (or country or
other jurisdiction, as the case may be) of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

 

	 	6.2.2.	 Due Authorization. It is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder and the persons executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate actions. 

  

	 	6.2.3.	 Binding Agreement. This Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable
principles and public policy. 

  

	 	6.2.4.	 No Conflicts. The execution, delivery and performance of this Agreement by it does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a PARTY or by which it may be bound. 

  

	 	6.2.5.	 Intellectual Property Rights. Each PARTY represents that it has valid and sufficient arrangements and
agreements with its directors, officers and employees (which term shall include agents, consultants and subcontractors) such that ownership of intellectual property rights in and to any Inventions made by its directors, officers and employees vests
in such PARTY. 

  

					
	Date: October 28, 2013	 	15 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	6.3.	 Additional Representations and Warranties by SELEXIS. SELEXIS hereby represents and warrants that, to
the best of its knowledge, as of the Effective Date: 

  

	 	6.3.1.	 There is no pending litigation asserting that the use of the SELEXIS Technology or the SELEXIS Know-How constitutes an infringement or misappropriation of any intellectual property rights of a Third Party; and 

  

	 	6.3.2.	 SELEXIS has the right in and to the SELEXIS Technology, SELEXIS
Know-How and the SELEXIS Patents to grant COMPANY the rights which are granted to COMPANY under this Agreement. 

  

	6.4.	 Additional Warranties by COMPANY. COMPANY hereby represents and warrants to SELEXIS that:

  

	 	6.4.1.	 To the best of its knowledge, there are no Third Party intellectual property rights or any other rights that
may be asserted against SELEXIS claiming that SELEXIS was or is directly infringing or is helping or assisting COMPANY in infringing such Third Party’s rights in connection with COMPANY’s exercise of the Commercial License granted by
SELEXIS hereunder (except to the extent that any such Third Party rights relate solely and specifically to the SELEXIS Technology and/or SELEXIS Materials), including, without limitation, the development, manufacture and commercialization of
Licensed Products and/or Final Products as permitted hereunder; and 

  

	 	6.4.2.	 As of the Effective Date, to the best of its knowledge, there is no litigation pending against COMPANY in
connection with the use or ownership of the Licensed Product, including, without limitation, the infringement or misappropriation of any intellectual property rights of a Third Party relating to the Licensed Product, and COMPANY has not received any
written claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights to such Third Party in connection with the use of the
Licensed Product. 

  

	 	6.4.3.	 COMPANY will use commercially reasonable endeavours to not knowingly misappropriate or infringe the
intellectual property or other rights of any Third Party in connection with its exercise of its licensed rights hereunder, including, without limitation, use of any SELEXIS Technology, Cell Line, or Deliverables, or development, manufacture or sale
of Licensed and/or Final Product hereunder. 

  

	6.5.	 Third Party Intellectual Property. Without limiting the warranty set forth in Article 6.4.3, COMPANY
hereby acknowledges that in order to make, have made, use, offer for sale, sell, import and otherwise exploit Licensed and/or Final Products in the Field it may require licenses under Third Party patent or other intellectual property rights that may
be infringed by the manufacture, use, offer for sale, sale, importation and other exploitation of Licensed and/or Final Product and, other than in the case of Third Party patent rights provided for in Article 5.6, it is agreed that it shall be
COMPANY’S responsibility to identify all such intellectual property and satisfy itself as to the need for such licences, and, if necessary, to obtain such licenses. COMPANY agrees that, with the sole exception of Third Party patent rights
provided for in Article 5.6 and for which SELEXIS provides indemnification in Article 7.1, SELEXIS will have no liability whatsoever for any infringement of Third Party patent rights. 

  

					
	Date: October 28, 2013	 	16 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	6.6.	 Disclaimer of Warranties by SELEXIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND WITHOUT
LIMITING THE GENERALITY OF ARTICLE 6.1, SELEXIS DOES NOT MAKE NOR GIVE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY
USE THEREOF BY SELEXIS OR BY COMPANY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. 

  

	7.	 Liability and Indemnification 

 

	7.1.	 Indemnification by SELEXIS. During the Term of this Agreement and thereafter, SELEXIS hereby agrees to
save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting directly from (i) any Third Party claim alleging that [***]; or
(ii) any material breach of SELEXIS’ representations, warranties and covenants set forth in Article 6; except in each case to the extent that such Losses were caused by willful misconduct or gross negligence of COMPANY or any of its
Affiliates, Collaborators or Sublicensees. In the event COMPANY seeks indemnification under this Article 7.1, COMPANY shall notify SELEXIS of any claim as soon as reasonably practicable after it receives notice of the claim. COMPANY shall allow
SELEXIS to conduct and control the defense against the claim (including without limitation to settle the claim solely for monetary consideration), shall (at SELEXIS’ expense) execute and deliver such documents and other papers and take such
further actions as may be reasonably required to defend against the claim (including without limitation to settle the claim solely for monetary consideration) and shall (at SELEXIS’ expense) cooperate as requested by SELEXIS in the defense of
the claim, provided always that SELEXIS may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express
written consent of COMPANY, which consent will not be unreasonably withheld. 

  

	7.2.	 Indemnification by COMPANY. During the Term of this Agreement and thereafter, COMPANY hereby agrees to
save, defend and hold SELEXIS and its officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting from (i) Third Party claims in connection with [***]; (ii) Third Party claims relating to [***];
or (iii) any material breach of COMPANY’s representations, warranties 

  

					
	Date: October 28, 2013	 	17 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
and covenants set forth in Article 6; in each case, except to the extent that such Losses result from the willful misconduct or gross negligence of SELEXIS. In the event SELEXIS seeks
indemnification under this Article, SELEXIS shall notify COMPANY of any claim as soon as reasonably practicable after it receives notice of the claim. SELEXIS shall allow COMPANY to assume direction and control of the defense of the claim (including
without limitation the right to settle the claim solely for monetary consideration), and shall (at COMPANY’s expense) execute and deliver such documents and other papers and take such further actions as may be reasonably required to defend
against the claim (including without limitation to settle the claim solely for monetary consideration). SELEXIS shall (at COMPANY’s expense) cooperate as requested by COMPANY in the defense of the claim, provided always that COMPANY may not
settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express written consent of SELEXIS, which consent will not
be unreasonably withheld. 

  

	7.3.	 No Incidental or Consequential Damages. In no event shall either PARTY be responsible for any incidental
or consequential damages, including without limitation, lost profits or opportunities; provided that the foregoing shall in no event limit a PARTY’s indemnification obligation under Article 7.1 or Article 7.2. 

 

	7.4.	 Limitation of Liability. SELEXIS’ cumulative liability under this Agreement, whether in contract,
in tort, or otherwise, shall in no event exceed the aggregate consideration paid by COMPANY to SELEXIS under this Agreement. 

  

	8.	 Confidentiality 

 

	8.1.	 Non-disclosure. During the Term of this Agreement and for [***]
thereafter, each PARTY shall keep Confidential Information of the other PARTY confidential and shall not (i) use the other PARTY’s Confidential Information for any purpose not expressly permitted under this Agreement, nor
(ii) disclose the other PARTY’s Confidential Information to any Person other than those of its agents, employees, and consultants (collectively, “Representatives”) who need to know such Confidential Information for a use or
purpose expressly permitted under this Agreement. Any such Representative who receives Confidential Information pursuant to this Article 8.1 shall be bound by written obligations of confidentiality and non-use
with respect to the Confidential Information that are no less stringent than the obligations set forth in this Agreement. 

  

	8.2.	 Exceptions. The confidentiality obligations set forth in Article 8.1 shall not apply to Confidential
Information that (i) is, or becomes, public information other than as the result of the violation of this Agreement or other 

  

					
	Date: October 28, 2013	 	18 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
act or omission by the receiving PARTY or its Representatives; (ii) was lawfully known to the receiving PARTY or its Representatives without restriction on use or disclosure at the time of
disclosure hereunder; (iii) is hereafter lawfully received by the receiving PARTY or its Representatives from a Third Party authorized to make such disclosure and without restriction on use or disclosure; or (iv) is approved for release by
prior written consent from the disclosing Party. 

  

	8.3.	 Authorized Disclosures. Notwithstanding any provision of this Agreement to the contrary, each PARTY may
disclose Confidential Information of the other PARTY to the extent such disclosure is required by law, provided however that the receiving PARTY gives the disclosing PARTY reasonable prior written notice to enable the disclosing PARTY to take
appropriate measures to protect its Confidential Information and fully cooperates, subject to commercially reasonable efforts, with the disclosing PARTY to prevent or limit to the greatest extent possible the disclosure of Confidential Information.

  

	8.4.	 Use of Name. No right, express or implied, is granted to either PARTY by this Agreement to use in any
manner any trademark or trade name of the other PARTY including the names “CIRCADIAN, VEGENICS or OPTHEA” and “SELEXIS” without the prior written consent of the PARTY entitled to such trademark or trade name.

  

	9.	 Term and Termination 

 

	9.1.	 Term. This Agreement is effective as of the Effective Date. Unless earlier terminated pursuant to
Articles 9.2, 9.3 or 9.4 of this Agreement shall remain in full force and effect until [***] (the “Term”). 

  

	9.2.	 Termination for Default. In addition to any other remedies which may be available at law or equity, in
the event of any material breach of this Agreement (the “Default”) by a PARTY (the “Defaulting Party”), the PARTY not in default (the “Non-Defaulting Party”)
shall have the right to give the Defaulting Party a written notice thereof (the “Notice of Default”), which must state the nature of the Default in reasonable details and request that the Defaulting Party cure such Default within
[***]. During such [***] period, the Parties will cooperate in good faith in order to resolve any issue(s) that may have given rise to the Notice of Default and/or cure such Default. If such Default is not cured or the issue(s) that may have given
rise to the Notice of Default not resolved within [***] after receipt of a Notice of Default by the Defaulting Party or if such Default cannot be cured, the Non-Defaulting Party may, at its sole discretion,
terminate this Agreement by written notice effective upon receipt. For avoidance of doubt, if the Default is cured or the issue(s) that may have given rise to the Notice of Default resolved within [***] after receipt of a Notice of Default by the
Defaulting Party, the Non-Defaulting Party may not terminate this Agreement. 

  

					
	Date: October 28, 2013	 	19 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	9.3.	 Termination for Bankruptcy. In the event that a PARTY shall become insolvent or make any arrangement
with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or
reconstruction (the “Insolvent Party”), the other PARTY shall have the right, at its sole discretion, to serve immediate notice of termination (with the sole exception of the circumstances expounded in 9.5.2.2) of this Agreement,
effective upon receipt. 

  

	9.4.	 Termination by COMPANY. COMPANY may terminate this Agreement at any time by giving [***] written notice
to SELEXIS. 

  

	9.5.	 Consequences of Expiration or Termination. 

 

	 	9.5.1.	 Termination of Licenses. In the event of a termination of this Agreement by COMPANY pursuant to Article
9.2 or 9.4, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. 

In the event of a termination of this Agreement by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this
Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3. 
  

	 	9.5.2.	 SELEXIS Technology and Confidential Information. 

 

	 	9.5.2.1	 Subject to the provisions of Article 9.5.2.2, upon termination of this Agreement under Article 9.2 or Article
9.3 where COMPANY is the Insolvent Party, or Article 9.4, COMPANY shall dispose of all tangible embodiments of the SELEXIS Technology and SELEXIS Confidential Information, including without limitation the SELEXIS Materials and Cell Lines, and render
inaccessible or useless all electronic embodiments, of SELEXIS Confidential Information provided to COMPANY by SELEXIS hereunder, except that COMPANY may retain one copy of the SELEXIS Confidential Information delivered hereunder in its secured
legal files only for ensuring compliance with the terms of this Agreement. 

  

	 	9.5.2.2	 Where the COMPANY is the Insolvent Party, SELEXIS acknowledges that this Agreement and the Commercial License
may constitute a material asset of the COMPANY and as such the continuation of this Agreement (and the exercise of the Commercial License) may be of benefit to both Parties, in particular where the Commercial License has been sublicensed. As such,
SELEXIS agrees to provide COMPANY or the COMPANY’S receiver or administrator the opportunity to make submissions for maintenance or restructure of the Agreement. Any submissions must be received by SELEXIS within [***] of the COMPANY

  

					
	Date: October 28, 2013	 	20 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	 	
entering into insolvency, receivership or administration. SELEXIS agrees to take into consideration any such submissions received within the [***] period before making any decision to terminate
the Agreement under Article 9.3. If no submissions are received within the [***] period or alternatively after due consideration of any submissions, SELEXIS shall have the right, at its sole discretion, to serve immediate notice of termination of
this Agreement under 9.3 and the COMPANY shall dispose of all tangible embodiments in accordance with 9.5.2.1. 

  

	 	9.5.3.	 COMPANY Confidential Information. Upon any expiration or termination of this Agreement, SELEXIS shall
dispose of all tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to SELEXIS by COMPANY hereunder, except that SELEXIS may retain one copy of the COMPANY Confidential
Information delivered hereunder in its secured legal files only for ensuring compliance with the terms of this Agreement. 

  

	 	9.5.4.	 Accrued Obligations. Expiration or termination of this Agreement shall not relieve the PARTIES of any
obligation or liability accruing prior to such expiration or termination. 

  

	10.	 Miscellaneous 

 

	10.1.	 Assignment. Neither this Agreement nor any interest hereunder shall be assignable by either PARTY
without the prior written consent of the other PARTY; provided, that either PARTY may assign this Agreement and all of its rights and obligations hereunder, without such prior written consent, to an entity which acquires all or substantially all of
the business or assets of such PARTY (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale or otherwise; and COMPANY may assign this Agreement and all of its rights and
obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder, and provided that [***]. This Agreement shall
be binding upon the successors and permitted assigns of the PARTIES and the name of a PARTY appearing herein shall be deemed to include the names of such PARTY’s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Article 10.1 shall be null and void. 

  

	10.2.	 Compliance with Governmental Obligations. Each PARTY shall comply, upon reasonable notice from the other
PARTY, with all governmental requests directed to either PARTY relating to this Agreement and provide all information and assistance necessary to comply with the governmental requests. 

  

					
	Date: October 28, 2013	 	21 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.3.	 Counterparts. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one PARTY but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. 

 

	10.4.	 Dispute Resolution. The PARTIES agree that in the event of a dispute between them arising from,
concerning or in any way relating to this Agreement, the PARTIES shall undertake good faith efforts to resolve any such dispute, with the matter being referred at the request of either PARTY to the General Counsel (or chief legal officer) of each
PARTY and, if remaining unresolved after [***], then to the Chief Executive Officers of each PARTY (or their designees). If after [***] of the matter first being referred to the General Counsel the PARTIES are unable to resolve such dispute, either
PARTY may seek any remedy available pursuant to Article 10.16. 

  

	10.5.	 Entire Agreement. This Agreement sets forth all of the covenants, promises, agreements, representations,
warranties, conditions and understandings between the PARTIES with respect to the subject matter hereof, and constitutes and contains the complete, final, and exclusive understanding and agreement of the PARTIES with respect to the subject matter
hereof, and cancels, supersedes and terminates all prior agreements and understanding between the PARTIES with respect to the subject matter hereof. There are no covenants, promises, agreements, representations, warranties, conditions or
understandings, whether oral or written, between the PARTIES other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the PARTIES hereto unless reduced to writing and signed by
the respective authorized officers of the PARTIES. For the avoidance of doubt, to the extent of any inconsistency between this Agreement and the Services Agreement, the terms of this Agreement shall govern and prevail. 

 

	10.6.	 Force Majeure. Neither PARTY shall be liable to the other for loss, damages, default or delay due to
Force Majeure, provided that the PARTY affected by a case of Force Majeure gives prompt notice of such case to the other PARTY. The PARTY giving such notice shall thereupon be excused from its obligations hereunder as it is thereby disabled from
performing for so long as it is so disabled, provided, however, that such affected PARTY commences and continues to take reasonable and diligent actions to cure such cause; and provided further that if any Force Majeure delays or prevents the
performance of the obligations of either PARTY for a continuous period in excess of [***], the PARTY not affected shall then be [***] written notice to the affected PARTY. [***]. 

 

	10.7.	 Further Actions. Each PARTY agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

  

					
	Date: October 28, 2013	 	22 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.8.	 Independent Contractors. The relationship between SELEXIS and COMPANY created by this Agreement is one
of independent contractors and neither PARTY shall have the power or authority to bind or obligate the other PARTY except as expressly set forth in this Agreement. 

 

	10.9.	 Interpretation of Agreement. Articles and other descriptive headings used in this Agreement are for
reference purposes only and shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa.

  

	10.10.	 License Obligations. Nothing in this Agreement imposes any obligation upon a PARTY to enter into any
other license or agreement with the other PARTY. 

  

	10.11.	 Notices. All notices and other communications required by this Agreement shall be in writing in the
English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
PARTIES at the following addresses (or at such other addresses that a PARTY specifies by like notice, provided, however, that notices of a change of address shall be effective only upon written receipt thereof): 

 

					
		 	If to COMPANY, addressed to:
		 	OPTHEA PTY LTD
		
		 	Level 4, 650 Chapel Street
		 	South Yarra	  	
		 	VIC 3141	  	
		 	Australia	  	
		 	Attention:	  	CEO
		 	Facsimile:	  	[***]

  

					
		 	If to SELEXIS, addressed to:
			
	 	 	 	  	Selexis S.A.
	 	 	 	  	[***]
			
		 	Attention:	  	[***]
		 	With a copy to:	  	[***]
		 	Facsimile:	  	[***]

  

  

					
	Date: October 28, 2013	 	23 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

	10.12.	 Binding Effect. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and
SELEXIS (and their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement. 

  

	10.13.	 Severability. If any term, covenant or condition of this Agreement or the application thereof to any
PARTY or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to PARTIES or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by applicable law. 

 

	10.14.	 Waiver. The failure on the part of a PARTY to exercise or enforce any rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. 

  

	10.15.	 Survival. Articles 1, 3.4, 4, 5, 6, 7, 8, 9.5 and 10 shall survive any termination or expiration of this
Agreement in accordance with their terms. 

  

	10.16.	 Governing Law and Jurisdiction. This Agreement shall be governed by and construed in accordance with the
substantive laws of [***], without regard to principles of conflict of laws. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts of [***]. 

  

					
	Date: October 28, 2013	 	24 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the PARTIES, having read the terms of this
Agreement and intending to be legally bound hereby, do hereby execute this Agreement: 
  

									
	SELEXIS SA	 		 	OPTHEA PTY LTD
					
	Signature:	 	/s/ Girod PA	 		 	Signature:	 	/s/ Megan Baldwin
					
	Place, Date:	 	 Plan-les-Ouates, Nov 15, 2013
	 		 	Place, Date:	 	Melbourne, 7 Nov 2013
			
	Name: Girod PA	 		 	Name: Megan Baldwin
			
	Title: Chief Scientific Officier	 		 	Title: CEO, Opthea P/L
		 		 	
					
		 		 		 		 	
					
	Signature:	 	/s/ Regine Brokamp	 		 	Signature:	 	/s/ Robert Klupacs
					
	Place, Date:	 	 PLO, Nov 15th 2013
	 		 	Place, Date:	 	Melbourne, 7 Nov 2013
			
	Name: Regine Brokamp	 		 	Name: Robert Klupacs
			
	Title: COO	 		 	Title: Director, Opthea Pty Limited

  

					
		 	25 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 EXHIBIT 1 

SELEXIS PATENT RIGHTS 
 Patent 1. 

 

			
	 Title
	  	[***]
		
	 Filing date
	  	[***]
		
	 Application Number
	  	[***]
		
	 Grant Patent Number
	  	[***]
		
	 Geographies
	  	[***]
		
	 Status
	  	[***]

 Patent 2. 
  

			
	 Title
	  	[***]
		
	 Filing date
	  	[***]
		
	 Application Number
	  	[***]
		
	 Publication Number
	  	[***]
		
	 Geographies
	  	[***]

  

					
	Date: October 28, 2013	 	26 of 27	 	Opthea
		 	Selexis SA	 	

 Certain information contained in this document, identified by [***], has been redacted
because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.  
 CONFIDENTIAL 
  

 EXHIBIT 2 

LICENSED PRODUCTS 
 Vascular Endothelial Growth Factor Receptor 3
soluble proteins 

  

					
	Date: October 28, 2013	 	27 of 27	 	Opthea
		 	Selexis SA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]